AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Skye Bioscience, Inc. Director's Dealing 2020

Aug 11, 2020

34097_dirs_2020-08-11_7986ff19-c5e7-4d22-93e7-54945e6eb29f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emerald Bioscience, Inc. (EMBI)
CIK: 0001516551
Period of Report: 2020-08-07-05:00

Reporting Person: DHILLON PUNIT (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-08-07-05:00	Common Stock	P	1000000	$100000	Acquired	1000000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-07-05:00	Employee Option Grant (Right to Buy)	$0.045	A	9000000	Acquired	2030-08-07-05:00	Common Stock (9000000)	Direct

Footnotes

F1: Private purchase transaction from Emerald Health Sciences at $0.10 per share.

F2: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all
Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four and a half years.